EGFR Rare Exon 18-21 Mutation

CI-VAR-00003956Explore in graph →CIViC 1863

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
EGFR Rare Exon 18-21 Mutation	Erlotinib + GefitinibSubstitutes	Predictive	B	Supports Sensitivity Response	4	accepted	EID4755 In a cohort of NSCLC patients treated with tyrosine kinase inhibitors erlotinib or gefitinib, 61 patients with uncommon mutations of unknown clinical significance (UMUCS) in EGFR exons 18-21 responded… (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC	civic
EGFR Rare Exon 18-21 Mutation	Erlotinib + GefitinibSubstitutes	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID4762 In a cohort of NSCLC patients tested for mutation in EGFR exons 18-21 a subset had uncommon mutations of unknown clinical significance (UMUCS). The most commonly occurring UMUCS were G719 and L861 mut… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.